SCHEMBL2322920

SCHEMBL2322920

Fc1ccc(-c2cc3c(nn2)C2CCC3C2)c(Cl)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 1/20 0.37
HSD11B1 P28845 2/20 0.35
HTR1A P08908 2/20 0.34
HTR7 P34969 1/20 0.34
CHRNB2 P17787 2/20 0.34
CHRNA4 P43681 2/20 0.34
SLC6A4 P31645 7/20 0.33
HTR2A P28223 2/20 0.33
HTR2C P28335 1/20 0.33
HTR2B P41595 1/20 0.33
CNR2 P34972 2/20 0.33
CHRNB4 P30926 1/20 0.32
CHRNA3 P32297 1/20 0.32
OPRL1 P41146 2/20 0.32
DRD1 P21728 1/20 0.32
SLC6A2 P23975 1/20 0.32
HTR1B P28222 1/20 0.32
SLC6A3 Q01959 1/20 0.32
MAPK14 Q16539 1/20 0.31
NPC1 O15118 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2322038 0.86 KMT2A (0.42) HSD11B1CHRNB2CHRNA4SLC6A4SLC6A3
SCHEMBL2322937 0.86 CYP11B1 (0.37) HTR1ACHRNB2CHRNA4SLC6A4HTR2A
SCHEMBL2321845 0.84 CYP11B1 (0.39) HTR1ACHRNB2CHRNA4SLC6A4HTR2A
SCHEMBL2325391 0.82 AR (0.40) HTR1ACHRNB2CHRNA4SLC6A4HTR2A
SCHEMBL2322258 0.79 NOTUM (0.34) HTR1ACHRNB2CHRNA4SLC6A4HTR2A
SCHEMBL2325039 0.78 CDK9 (0.40) HTR2AHTR2CHTR2B
SCHEMBL2322727 0.78 CNR2 (0.39) CHRNB2CHRNA4SLC6A4HTR2BCNR2
SCHEMBL2325609 0.77 CNR2 (0.44) CNR2SLC6A3
SCHEMBL2323614 0.76 NPC1 (0.36) NPC1RAB9A
SCHEMBL2325997 0.76 NOTUM (0.38) HSD11B1CHRNB2CHRNA4SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904455-B1 PYRIDAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-17 EP claimed
US-7678795-B2 Pyridazines as 11b-HSD1 inhibitors HOFFMAN-LA ROCHE INC. (US) 2010-03-16 US claimed
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. 2007-01-11 US claimed
EP-1904455-B1 PYRIDAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-17 EP disclosed
US-7678795-B2 Pyridazines as 11b-HSD1 inhibitors HOFFMAN-LA ROCHE INC. (US) 2010-03-16 US disclosed
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HSD11B1, HSD17B1, HSD17B11 NISCH 3514/4885HSD11B1 1/4885HTR1A 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.